Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

ATHE Alterity Therapeutics Limited

1,9612

0,0012 (0,06%)

21 Mai 2024 - Geschlossen

Verzögert um 15 Minuten

Form EFFECT - Notice of Effectiveness

Alterity Therapeutics (NASDAQ:ATHE)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Alterity Therapeutics Charts.

Alterity Therapeutics (NASDAQ:ATHE)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Alterity Therapeutics Charts.

News Alterity Therapeutics Limited

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
Mittwoch 8 Mai 2024 (2 Wochen vor) • GlobeNewswire Inc.

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
Dienstag 30 April 2024 (3 Wochen vor) • GlobeNewswire Inc.

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
Montag 29 April 2024 (3 Wochen vor) • GlobeNewswire Inc.

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
Mittwoch 17 April 2024 (1 Monat vor) • GlobeNewswire Inc.

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
Mittwoch 10 April 2024 (1 Monat vor) • GlobeNewswire Inc.

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
Dienstag 26 März 2024 (2 Monate vor) • GlobeNewswire Inc.

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
Dienstag 20 Februar 2024 (3 Monate vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Donnerstag 15 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Donnerstag 15 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
Dienstag 6 Februar 2024 (3 Monate vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mittwoch 31 Januar 2024 (4 Monate vor) • Edgar (US Regulatory)

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
Montag 29 Januar 2024 (4 Monate vor) • GlobeNewswire Inc.

Weitere Alterity Therapeutics Limited News-Artikel

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen